Bulk Pharmaceutical API Sources for LEVOLEUCOVORIN

Bulk Pharmaceutical API Sources for LEVOLEUCOVORIN

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		149436
ABI Chem		AC1L3Z4B
ChemTik		CTK5C8151
A&J Pharmtech CO., LTD.		AJ-70567

Bulk Active Pharmaceutical Ingredient (API) Sources for Levoleucovorin

Last updated: February 19, 2026

This report details bulk active pharmaceutical ingredient (API) sourcing for levoleucovorin. It identifies key manufacturers, regulatory landscapes, and market dynamics impacting supply.

What is Levoleucovorin?

Levoleucovorin is the pharmacologically active isomer of leucovorin, also known as folinic acid. It is a reduced form of folic acid used in medicine primarily to counteract the adverse effects of folate antagonists like methotrexate. Leucovorin is administered to "rescue" normal cells from the toxicity of chemotherapy agents that inhibit dihydrofolate reductase. Levoleucovorin has a higher potency per unit mass compared to racemic leucovorin, allowing for lower doses.

Chemical Structure and Properties

Levoleucovorin is chemically known as L-leucovorin, or (6S)-5-formyltetrahydrofolate. Its molecular formula is C20H23N7O7, and its molecular weight is 473.44 g/mol. It is a water-soluble crystalline powder.

Therapeutic Applications

• Methotrexate Rescue: Levoleucovorin is a standard treatment following high-dose methotrexate therapy in various cancers, including osteosarcoma and certain leukemias. It bypasses the dihydrofolate reductase enzyme, providing reduced folate cofactors to healthy cells and preventing bone marrow suppression.
• Colorectal Cancer: In combination with 5-fluorouracil (5-FU), levoleucovorin enhances the cytotoxic effects of 5-FU in the treatment of metastatic colorectal cancer. It stabilizes the binding of 5-FU's active metabolite to thymidylate synthase, an enzyme critical for DNA synthesis.
• Leucovorin Resistance: While less common, it can be used in situations where standard leucovorin is less effective.

Global API Manufacturing Landscape

The production of levoleucovorin API is concentrated among a limited number of manufacturers, primarily in Asia. Key factors influencing sourcing decisions include manufacturing capacity, regulatory compliance, quality control, and price.

Major API Manufacturers

Several companies globally produce bulk levoleucovorin API. These entities often operate under stringent quality management systems and are subject to audits by regulatory bodies and pharmaceutical companies.

Table 1: Identified Levoleucovorin API Manufacturers

Manufacturer Name	Country of Origin	Primary Markets Served	Key Certifications/Audits (Examples)
Tai Chem Industrial Co., Ltd.	China	Global	FDA, EDQM, PMDA, WHO GMP
Nantong Aspire Pharmaceutical Co., Ltd.	China	Global	FDA, EDQM, WHO GMP
Zhejiang NHU Co., Ltd.	China	Global	FDA, EDQM, PMDA, WHO GMP
Zhejiang Medicine Co., Ltd.	China	Global	FDA, EDQM, PMDA, WHO GMP
Ani Pharmaceutical Co., Ltd.	China	Global	FDA, EDQM, WHO GMP
Hetero Drugs Ltd.	India	Global	FDA, EDQM, WHO GMP
Dr. Reddy's Laboratories	India	Global	FDA, EDQM, WHO GMP

Note: Certifications are subject to change and require direct verification with the manufacturer and relevant regulatory agencies. This list is not exhaustive and represents commonly cited suppliers.

Manufacturing Processes and Technologies

The synthesis of levoleucovorin involves complex multi-step chemical processes. Key steps often include the reduction of folic acid to tetrahydrofolate, followed by formylation at the N5 position. Stereoselective synthesis or chiral resolution techniques are essential to obtain the pure L-isomer.

Common Synthetic Strategies:

1. Chiral Resolution: Racemic leucovorin is synthesized, and then the L-isomer is separated using chiral chromatography or diastereomeric salt formation.
2. Asymmetric Synthesis: Employing chiral catalysts or reagents to directly synthesize the L-isomer with high enantiomeric purity.

The choice of synthesis route impacts cost, yield, purity, and environmental considerations. Manufacturers are increasingly investing in greener chemistry approaches to reduce solvent usage and waste.

Regulatory Landscape and Compliance

The approval and manufacturing of levoleucovorin API are governed by stringent regulatory requirements worldwide. Pharmaceutical companies sourcing API must ensure their suppliers meet these standards.

Key Regulatory Agencies and Guidelines

• U.S. Food and Drug Administration (FDA): Requires Current Good Manufacturing Practices (cGMP) compliance. Drug Master Files (DMFs) are typically submitted to support drug product applications.
• European Medicines Agency (EMA) / European Directorate for the Quality of Medicines & HealthCare (EDQM): Compliance with European Pharmacopoeia (Ph. Eur.) standards and Certificates of Suitability (CEPs) are critical for the European market.
• Pharmaceuticals and Medical Devices Agency (PMDA) Japan: Mandates adherence to Japanese GMP and specific registration processes.
• World Health Organization (WHO): Issues GMP certifications for manufacturers supplying to countries with national regulatory authorities that recognize WHO standards.

Good Manufacturing Practices (GMP)

Adherence to GMP is non-negotiable for API manufacturers. This includes rigorous controls over:

• Quality Management Systems: Robust quality control and quality assurance protocols.
• Facility and Equipment: Proper design, maintenance, and calibration of manufacturing facilities and equipment.
• Personnel: Adequate training and qualification of all personnel involved in manufacturing.
• Raw Material Control: Strict testing and approval of all incoming raw materials.
• Process Validation: Demonstrated consistency and reproducibility of manufacturing processes.
• Documentation and Record-Keeping: Comprehensive and accurate documentation of all manufacturing activities.
• Change Control: Formal procedures for managing any changes to manufacturing processes or materials.

Impurity Profiling and Control

Controlling impurities, including enantiomeric impurities, process-related impurities, and degradation products, is critical. Pharmacopoeial monographs (e.g., USP, Ph. Eur.) define acceptable limits for specific impurities. Manufacturers must develop validated analytical methods for impurity detection and quantification.

Market Dynamics and Supply Chain Considerations

The levoleucovorin API market is influenced by demand from the oncology sector, patent expiries of innovator products, and the competitive landscape among API suppliers.

Demand Drivers

• Oncology Treatment Trends: The increasing incidence of cancers treated with methotrexate or 5-FU drives demand.
• Off-Patent Products: Generic levoleucovorin formulations increase the need for bulk API from multiple sources.
• Emerging Markets: Growing healthcare access in developing nations contributes to demand.

Supply Chain Risks

• Geopolitical Factors: Concentration of manufacturing in specific regions can create vulnerabilities to supply disruptions due to trade policies, political instability, or natural disasters.
• Regulatory Hurdles: Changes in regulatory requirements or successful inspections can impact a manufacturer's ability to supply.
• Quality Issues: A single batch failure or recall can significantly disrupt supply and impact the reputation of both the API supplier and the drug product manufacturer.
• Price Volatility: Raw material costs, manufacturing efficiencies, and market competition can lead to price fluctuations.

Sourcing Strategies for Pharmaceutical Companies

Pharmaceutical companies require a robust sourcing strategy to ensure a stable and reliable supply of high-quality levoleucovorin API. This typically involves:

• Supplier Qualification: Thorough due diligence, including site audits, review of quality systems, and assessment of regulatory compliance.
• Dual Sourcing: Establishing relationships with at least two qualified suppliers to mitigate supply chain risks.
• Long-Term Contracts: Securing supply and favorable pricing through strategic agreements.
• Technical Collaboration: Working closely with API manufacturers on process optimization, impurity control, and analytical method development.
• Inventory Management: Maintaining appropriate safety stock levels to buffer against unexpected demand spikes or supply interruptions.

Quality Control and Analytical Testing

Ensuring the quality of levoleucovorin API is paramount. This involves comprehensive testing to confirm identity, purity, potency, and compliance with pharmacopoeial standards.

Key Quality Attributes

• Assay: Determination of the levoleucovorin content, typically by High-Performance Liquid Chromatography (HPLC).
• Chiral Purity: Verification of the enantiomeric excess of the L-isomer. This is crucial, as the D-isomer may have different pharmacological properties or be inactive. Methods like chiral HPLC are employed.
• Related Substances/Impurities: Identification and quantification of known and unknown impurities, including residual solvents, starting materials, intermediates, and degradation products.
• Loss on Drying/Water Content: Measurement of moisture content.
• Heavy Metals: Testing for unacceptable levels of heavy metal contaminants.
• Microbial Limits: Ensuring compliance with acceptable microbial contamination levels.
• Identification: Confirming the identity of the substance using techniques such as Infrared (IR) spectroscopy or Nuclear Magnetic Resonance (NMR) spectroscopy.

Pharmacopoeial Standards

Levoleucovorin is described in various pharmacopoeias, including:

• United States Pharmacopeia (USP): Leucovorin Calcium (levoleucovorin is often used as its calcium salt).
• European Pharmacopoeia (Ph. Eur.): Acid folinic (often refers to the racemic mixture, but monographs may address specific isomers or require testing for enantiomeric purity).
• Japanese Pharmacopoeia (JP): Folinic Acid.

Manufacturers must demonstrate compliance with the relevant pharmacopoeial monograph for the target market.

Economic Considerations and Pricing

The pricing of levoleucovorin API is influenced by manufacturing costs, economies of scale, market competition, and regulatory compliance expenses.

Cost Components

• Raw Materials: Cost of starting materials and reagents.
• Manufacturing Expenses: Labor, energy, equipment depreciation, and waste disposal.
• Quality Control: Analytical testing and batch release.
• Regulatory Compliance: GMP adherence, DMF filing, and audit costs.
• Yield and Efficiency: Higher yields and efficient processes reduce per-unit costs.

Market Pricing Trends

Historically, levoleucovorin pricing has been relatively stable, influenced by established generic competition and consistent demand. However, fluctuations can occur due to:

• New Entrants: Emergence of new API manufacturers can increase competition and potentially lower prices.
• Regulatory Changes: Increased compliance costs can be passed on to customers.
• Supply Disruptions: Shortages can lead to temporary price spikes.

Precise pricing data is proprietary and subject to direct negotiation between buyers and sellers. However, industry estimates place API costs for complex molecules like levoleucovorin in the range of several hundred to a few thousand USD per kilogram, depending on volume, quality, and supplier.

Future Outlook

The market for levoleucovorin API is expected to remain stable, driven by its established role in oncology. Innovations may focus on more efficient and environmentally friendly synthesis routes. The continued globalization of pharmaceutical manufacturing and regulatory convergence will shape supplier landscapes.

Innovation in Synthesis

Research into stereoselective synthesis methods could lead to more cost-effective and higher-purity levoleucovorin production. Advances in continuous manufacturing could also offer opportunities for improved efficiency.

Regulatory Harmonization

Ongoing efforts towards global regulatory harmonization may simplify market access for API manufacturers who meet high, internationally recognized standards.

Supply Chain Resilience

Increasing awareness of supply chain vulnerabilities will likely drive greater emphasis on diversification of sourcing and enhanced supplier relationship management.

Key Takeaways

• Levoleucovorin API is primarily manufactured by a concentrated group of companies, predominantly in China and India.
• Stringent regulatory compliance (FDA, EMA, EDQM, PMDA) and adherence to GMP are critical for API suppliers.
• Quality control, particularly chiral purity and impurity profiling, is paramount.
• Pharmaceutical companies must implement robust sourcing strategies, including supplier qualification and dual sourcing, to ensure supply chain resilience.
• The market is influenced by oncology treatment trends and generic competition.

FAQs

1. What are the primary regulatory requirements for a levoleucovorin API supplier to serve the US market? Suppliers must comply with US FDA’s Current Good Manufacturing Practices (cGMP). This typically involves the submission and acceptance of a Drug Master File (DMF) by the FDA for the API, detailing manufacturing processes, controls, and stability data. Regular FDA inspections of manufacturing facilities are also a critical component.

2. How is the enantiomeric purity of levoleucovorin API typically verified? Enantiomeric purity is primarily verified using chiral High-Performance Liquid Chromatography (HPLC). This analytical technique separates enantiomers, allowing for the quantification of the L-isomer (levoleucovorin) and any D-isomer present. Pharmacopoeial monographs often specify acceptance criteria for enantiomeric purity.

3. What are the main risks associated with sourcing levoleucovorin API from a single supplier? The primary risks include supply chain disruption due to unforeseen events such as geopolitical issues, natural disasters, quality failures, regulatory actions against the supplier, or capacity constraints. This can lead to stockouts, production delays, and significant financial losses for drug product manufacturers.

4. Which pharmacopoeias provide monographs for levoleucovorin or its related forms? Key pharmacopoeias that provide monographs relevant to levoleucovorin include the United States Pharmacopeia (USP), which often covers leucovorin calcium, the European Pharmacopoeia (Ph. Eur.) with a monograph for folinic acid, and the Japanese Pharmacopoeia (JP) for folinic acid.

5. Are there specific analytical challenges in detecting and quantifying impurities in levoleucovorin API? Yes, analytical challenges can arise from the complex chemical structure of levoleucovorin and its degradation pathways. Identifying and quantifying structurally similar impurities, enantiomeric impurities, and process-related impurities requires sophisticated analytical methods, such as HPLC with UV or Mass Spectrometry detection, and potentially gas chromatography for residual solvents. Method validation is crucial to ensure accuracy and reliability.

Citations

[1] Tai Chem Industrial Co., Ltd. (n.d.). Levoleucovorin Calcium. Retrieved from [Manufacturer's official website or product catalog - specific URL required for formal citation]

[2] Nantong Aspire Pharmaceutical Co., Ltd. (n.d.). Levoleucovorin API. Retrieved from [Manufacturer's official website or product catalog - specific URL required for formal citation]

[3] Zhejiang NHU Co., Ltd. (n.d.). Levoleucovorin. Retrieved from [Manufacturer's official website or product catalog - specific URL required for formal citation]

[4] Zhejiang Medicine Co., Ltd. (n.d.). Levoleucovorin. Retrieved from [Manufacturer's official website or product catalog - specific URL required for formal citation]

[5] Ani Pharmaceutical Co., Ltd. (n.d.). Levoleucovorin Calcium. Retrieved from [Manufacturer's official website or product catalog - specific URL required for formal citation]

[6] Hetero Drugs Ltd. (n.d.). Levoleucovorin API. Retrieved from [Manufacturer's official website or product catalog - specific URL required for formal citation]

[7] Dr. Reddy's Laboratories. (n.d.). Levoleucovorin API. Retrieved from [Manufacturer's official website or product catalog - specific URL required for formal citation]

[8] United States Pharmacopeia. (2023). Leucovorin Calcium. In United States Pharmacopeia and National Formulary. [Specific USP/NF edition and page numbers required for formal citation]

[9] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from [EDQM official website or Ph. Eur. database - specific reference required for formal citation]

[10] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: Drug Master Files: A Gateway to Public-Private Information. Retrieved from [FDA official website - specific URL required for formal citation]